I am first and foremost a clinician with a practice dedicated to treating patients with benign and malignant breast disease. I have a strong commitment to education and research and am ranked in the top 0.072% of the world’s breast cancer experts based on publication output in the past 10 years.
My principle research interest is exploration of the fluorescent tracer agent indocyanine green (ICG) for sentinel lymph node detection in early breast cancer patients. I was joint recipient of an ABS Research Development Grant in 2021 and will be conducting a randomised clinical trial of ICG in collaboration with colleagues in Dundee. I am Principal Investigator for several national breast cancer trials and regularly act as reviewer for major grant giving bodies such as Cancer Research UK, the Medical Research Council, Breast Cancer Now and several key European cancer research foundations.
I regularly undertake international invited speaker presentations and in 2019 traveled to Iran, Jordan, Italy, Kenya, Switzerland, Russia, Spain, Taiwan, India, Brazil and the United States. I am interested in promoting breast cancer care in low and middle income countries and traveled to Nairobi in August 2019 to deliver a workshop and lectures to local surgeons; I am currently developing a resource of online educational materials.
I was a member of a Parliamentary Working Group in 2017 on management of benign breast lesions and those of uncertain malignant potential.
My extensive and up-to-date knowledge in the field of breast cancer was recognised internationally with my nomination to become a reviewer for the American Society of Clinical Oncology (ASCO) guidelines that influence clinical practice worldwide and are adopted by many countries as standard of care for breast cancer patients.